目的探究TK-1在非小细胞肺癌中的治疗及耐药问题。方法将我院2014年2月至2016年5月收治的100例非小细胞肺癌患者作为研究对象,在小分子化合物停药后给予化疗,分析其近期疗效及毒副反应。结果 100例患者15例进展、73例稳定、12例部分缓解,疾病控制率85%,疾病进展5.2个月,15例交替治疗之后仍进展;本组患者皮疹发生率63%,皮肤瘙痒发生率21%,腹泻发生率28%,甲沟炎发生率27%,转氨酶增高发生率14%,均可耐受。结论 TK-1治疗疾病进展后和化疗交替治疗能够将小分子化合物的敏感性部分恢复,毒副反应可耐受,具有治疗有效性。 Objective To investigate the treatment and drug resistance of TK-1 in non-small cell lung cancer. Methods A total of 100 non-small cell lung cancer patients from February 2014 to May 2016 in our hospital were enrolled in this study. Chemotherapy was given after the small molecule compounds were discontinued. The curative effect and toxicity were also analyzed. Results 100 patients progressed in 15 cases, 73 patients were stable, 12 patients were partly relieved, the disease control rate was 85%, the disease progression was 5.2 months and 15 patients were still progressing after alternating therapy. The incidence of rash in this group was 63% and the incidence of pruritus 21%, the incidence of diarrhea 28%, incidence of paronychia 27%, aminotransferase increased incidence of 14%, can be tolerated. CONCLUSIONS: TK-1 is capable of partially reversing the sensitivity of small molecule compounds after treatment of disease progression and alternation of chemotherapy. The toxic side effects are tolerable and therapeutically effective.